VIDEO: LAMP study focuses on atropine for myopia control

ByMark A. Bullimore, MCOptom, PhD, FAAO, FARVO

ByDavid W. Mullin

ByGeorgia I Salvaryn

Fact checked byChristine Klimanskis, ELS

NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Mark A. Bullimore, MCOptom, PhD, FAAO, discussed the use of atropine for myopia control in the LAMP study.

“One of the challenges is that [the LAMP study] only had control data in the first year because for ethical reasons, after 1 year, the control patients were switched to a concentration of atropine,” Bullimore, of the University of Houston College of Optometry, said.

Reference:

Bullimore MA, et al. Ophthalmology. 2023;doi:10.1016/j.ophtha.2023.02.020.

Published by:

Sources/Disclosures

Collapse

Source:

Bullimore MA, et al. Efficacy in myopia control — Three-year predictions from the LAMP study. Presented at: Association for Research in Vision and Ophthalmology meeting; April 23-27, 2023; New Orleans.

Disclosures: Bullimore reports consulting for Alcon Research, CooperVision, CorneaGen, EssilorLuxottica, Euclid Systems, Eyenovia, Genentech, Johnson & Johnson Vision, Lentechs, Novartis, Paragon Vision Sciences and Vyluma.

ARVO

Read more

VIDEO: LAMP study focuses on atropine for myopia control

Reference:

Related Content